← Back to Clinical Trials
Recruiting NCT07592962

NCT07592962 Whole-life Investigation of Lishui Longevity

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07592962
Status Recruiting
Phase
Sponsor The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital
Condition Ischemic Stroke
Study Type OBSERVATIONAL
Enrollment 4,500 participants
Start Date 2026-05-18
Primary Completion 2036-05-31

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 80 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 4,500 participants in total. It began in 2026-05-18 with a primary completion date of 2036-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

1. To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors. 2. To carry out targeted intervention and long-term follow-up for high-risk populations, reduce the incidence risk of major chronic diseases in the target population, improve residents' health status and grassroots comprehensive prevention and treatment capacity of chronic diseases, and provide scientific evidence and practical support for the construction of Healthy Lishui.

Eligibility Criteria

Inclusion Criteria: * Aged 30 to 80 years old; male-to-female ratio of 1:1; permanent residents in Lishui City; physically healthy; voluntary participation in the project with signed informed consent. Exclusion Criteria: * Individuals ever diagnosed with malignant tumors or cardiovascular and cerebrovascular diseases by physicians or other health professionals; those with unstable vital signs or an expected survival time of less than 3 months; participants with incomplete basic information, and those unable to cooperate with subsequent follow-up.

Contact & Investigator

Central Contact

Jingping Sun, PhD

✉ lszxyysunjingping@yeah.net

📞 86-18504713450

Principal Investigator

Jiansong Ji, PhD

STUDY CHAIR

The Central Hospital of Lishui City

Frequently Asked Questions

Who can join the NCT07592962 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 80 Years, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07592962 currently recruiting?

Yes, NCT07592962 is actively recruiting participants. Contact the research team at lszxyysunjingping@yeah.net for enrollment information.

Where is the NCT07592962 trial being conducted?

This trial is being conducted at Lishui, China.

Who is sponsoring the NCT07592962 clinical trial?

NCT07592962 is sponsored by The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital. The principal investigator is Jiansong Ji, PhD at The Central Hospital of Lishui City. The trial plans to enroll 4,500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology